LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

Search

Harvard Bioscience Inc

Închisă

SectorSănătate

0.54 -8.47

Rezumat

Modificarea prețului

24h

Curent

Minim

0.53

Maxim

0.6

Indicatori cheie

By Trading Economics

Venit

1.1M

-1.2M

Vânzări

141K

21M

Marjă de profit

-5.978

Angajați

330

EBITDA

1M

1.2M

Dividende

By Dow Jones

Următoarele câștiguri

12 mar. 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-1.9M

24M

Deschiderea anterioară

9.01

Închiderea anterioară

0.54

Sentimentul știrilor

By Acuity

17%

83%

23 / 352 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bearish Evidence

Harvard Bioscience Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

11 feb. 2026, 23:47 UTC

Acțiuni populare

Stocks to Watch: AppLovin, Cisco, Cognex, Pilgrim's Pride

11 feb. 2026, 22:59 UTC

Câștiguri
Achiziții, Fuziuni, Preluări

Grab Holdings to Buy U.S.-Based Stash Financial

11 feb. 2026, 23:54 UTC

Câștiguri

McDonald's Says Its Value Campaign Is Paying Off -- 2nd Update

11 feb. 2026, 23:50 UTC

Market Talk

Global Equities Roundup: Market Talk

11 feb. 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for Takaichi's Economic Steps -- Market Talk

11 feb. 2026, 23:49 UTC

Câștiguri

Singtel: Key Focus Areas Are Strengthening Core Businesses, Scaling Growth Engines, Building Momentum Across Regional Associates >Z74.SG

11 feb. 2026, 23:45 UTC

Câștiguri

Singtel: Net Exceptional Gain of S$1.15B in 3Q Primarily From Sale of Partial Stake in Bharti Airtel>Z74.SG

11 feb. 2026, 23:42 UTC

Câștiguri

Singtel 3Q Underlying Net Profit S$744M Vs. S$680M >Z74.SG

11 feb. 2026, 23:41 UTC

Câștiguri

Singtel 3Q Net S$1.89B Vs. Net S$1.32B >Z74.SG

11 feb. 2026, 23:40 UTC

Câștiguri

Singtel 3Q Operating Revenue S$3.66B Vs. S$3.63B >Z74.SG

11 feb. 2026, 23:35 UTC

Market Talk

Gold Falls on Prospects of Long Fed Pause -- Market Talk

11 feb. 2026, 23:18 UTC

Market Talk

AppLovin CEO Looks to Soothe Concerns Over AI, Competition -- Market Talk

11 feb. 2026, 23:14 UTC

Market Talk

RBA Governor Faces Barrage of Questions About Govt Spending -- Market Talk

11 feb. 2026, 22:59 UTC

Câștiguri

Kakao 2025 Net KRW525.72B Vs. Loss KRW161.87B >035720.SE

11 feb. 2026, 22:59 UTC

Câștiguri

Kakao 2025 Oper Pft KRW732.04B Vs. Pft KRW460.21B >035720.SE

11 feb. 2026, 22:59 UTC

Câștiguri

Kakao 2025 Rev KRW8.099T Vs. KRW7.872T >035720.SE

11 feb. 2026, 22:58 UTC

Câștiguri

Kakao 4Q Net Loss Missed FactSet-Compiled Consensus

11 feb. 2026, 22:57 UTC

Câștiguri

Kakao 4Q Loss KRW39.30B Vs. Loss KRW395.21B >035720.SE

11 feb. 2026, 22:54 UTC

Câștiguri

Kakao 4Q Oper Pft KRW203.45B Vs. Pft KRW75.43B >035720.SE

11 feb. 2026, 22:53 UTC

Câștiguri

Kakao 4Q Rev KRW2.133T Vs. KRW1.957T >035720.SE

11 feb. 2026, 22:47 UTC

Câștiguri

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11 feb. 2026, 22:47 UTC

Câștiguri

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11 feb. 2026, 22:23 UTC

Câștiguri

Grab Holdings Expects to Close Stash Acquisition in 3Q of 2026 >GRAB

11 feb. 2026, 22:22 UTC

Câștiguri

Grab Holdings to Acquire U.S. Digital Financial Services Company Stash Financial >GRAB

11 feb. 2026, 22:22 UTC

Câștiguri

Grab Holdings Sees FY26 Adj Ebitda $700M to $720M >GRAB

11 feb. 2026, 22:19 UTC

Câștiguri

Grab Holdings Sees FY26 Rev $4.04B to $4.10B >GRAB

11 feb. 2026, 22:18 UTC

Câștiguri

Grab Holdings 4Q Adj Ebitda $148.0M Vs. $97.0M >GRAB

11 feb. 2026, 22:18 UTC

Câștiguri

Grab Holdings 4Q Net $153.0M Vs. Net $11.0M >GRAB

11 feb. 2026, 22:18 UTC

Câștiguri

Grab Holdings 4Q Oper Pft $52.0M Vs. $2.0M >GRAB

11 feb. 2026, 22:16 UTC

Câștiguri

Grab Holdings 4Q Rev $906.0M Vs. $764.0M >GRAB

Comparație

Modificare preț

Harvard Bioscience Inc Așteptări

Consens privind evaluarea

By TipRanks

0 ratings

0

Cumpărare

0

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

0.3 / 0.3401Suport & Rezistență

Termen scurt

Weak Bearish Evidence

Termen mediu

No Evidence

Termen lung

No Evidence

Sentiment

By Acuity

23 / 352 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Peste medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre Harvard Bioscience Inc

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
help-icon Live chat